1
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
2
|
Kang TW, Lim HK and Cha DI: Aggressive
tumor recurrence after radiofrequency ablation for hepatocellular
carcinoma. Clin Mol Hepatol. 23:95–101. 2017. View Article : Google Scholar : PubMed/NCBI
|
3
|
Germani G, Pleguezuelo M, Gurusamy K,
Meyer T, Isgrò G and Burroughs AK: Clinical outcomes of
radiofrequency ablation, percutaneous alcohol and acetic acid
injection for hepatocelullar carcinoma: A meta-analysis. J Hepatol.
52:380–388. 2010. View Article : Google Scholar : PubMed/NCBI
|
4
|
Lee HY, Rhim H, Lee MW, Kim YS, Choi D,
Park MJ, Kim YK, Kim SH and Lim HK: Early diffuse recurrence of
hepatocellular carcinoma after percutaneous radiofrequency
ablation: Analysis of risk factors. Eur Radiol. 23:190–197. 2013.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Obara K, Matsumoto N, Okamoto M, Kobayashi
M, Ikeda H, Takahashi H, Katakura Y, Matsunaga K, Ishii T, Okuse C,
et al: Insufficient radiofrequency ablation therapy may induce
further malignant transformation of hepatocellular carcinoma.
Hepatol Int. 2:116–123. 2008. View Article : Google Scholar : PubMed/NCBI
|
6
|
Ke S, Ding XM, Kong J, Gao J, Wang SH,
Cheng Y and Sun WB: Low temperature of radiofrequency ablation at
the target sites can facilitate rapid progression of residual
hepatic VX2 carcinoma. J Transl Med. 8:732010. View Article : Google Scholar : PubMed/NCBI
|
7
|
Yoshida S, Kornek M, Ikenaga N, Schmelzle
M, Masuzaki R, Csizmadia E, Wu Y, Robson SC and Schuppan D:
Sublethal heat treatment promotes epithelial-mesenchymal transition
and enhances the malignant potential of hepatocellular carcinoma.
Hepatology. 58:1667–1680. 2013. View Article : Google Scholar : PubMed/NCBI
|
8
|
Liu Z, Dai H, Jia G, Li Y, Liu X and Ren
W: Insufficient radiofrequency ablation promotes human hepatoma
SMMC7721 cell proliferation by stimulating vascular endothelial
growth factor overexpression. Oncol Lett. 9:1893–1896. 2015.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Ma S: Biology and clinical implications of
CD133(+) liver cancer stem cells. Exp Cell Res. 319:126–132. 2013.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Tong CM, Ma S and Guan XY: Biology of
hepatic cancer stem cells. J Gastroenterol Hepatol. 26:1229–1237.
2011. View Article : Google Scholar : PubMed/NCBI
|
11
|
Yang S, Wang X, Contino G, Liesa M, Sahin
E, Ying H, Bause A, Li Y, Stommel JM, Dell'antonio G, et al:
Pancreatic cancers require autophagy for tumor growth. Genes Dev.
25:717–729. 2011. View Article : Google Scholar : PubMed/NCBI
|
12
|
Wu DH, Jia CC, Chen J, Lin ZX, Ruan DY, Li
X, Lin Q, Min-Dong, Ma XK, Wan XB, et al: Autophagic LC3B
overexpression correlates with malignant progression and predicts a
poor prognosis in hepatocellular carcinoma. Tumour Biol.
35:12225–12233. 2014. View Article : Google Scholar : PubMed/NCBI
|
13
|
Chang Y, Yan W, He X, Zhang L, Li C, Huang
H, Nace G, Geller DA, Lin J and Tsung A: miR-375 inhibits autophagy
and reduces viability of hepatocellular carcinoma cells under
hypoxic conditions. Gastroenterology. 143:177–87.e8. 2012.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Peng WX, Xiong EM, Ge L, Wan YY, Zhang CL,
Du FY, Xu M, Bhat RA, Jin J and Gong AH: Egr-1 promotes
hypoxia-induced autophagy to enhance chemo-resistance of
hepatocellular carcinoma cells. Exp Cell Res. 340:62–70. 2016.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Pinheiro C, Longatto-Filho A, Scapulatempo
C, Ferreira L, Martins S, Pellerin L, Rodrigues M, Alves VA,
Schmitt F and Baltazar F: Increased expression of monocarboxylate
transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch.
452:139–146. 2008. View Article : Google Scholar : PubMed/NCBI
|
16
|
Chen YJ, Chi CW, Su WC and Huang HL:
Lapatinib induces autophagic cell death and inhibits growth of
human hepatocellular carcinoma. Oncotarget. 5:4845–4854. 2014.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Kader M, Alaoui-El-Azher M, Vorhauer J,
Kode BB, Wells JZ, Stolz D, Michalopoulos G, Wells A, Scott M and
Ismail N: MyD88-dependent inflammasome activation and autophagy
inhibition contributes to Ehrlichia-induced liver injury and toxic
shock. PLoS Pathog. 13:e10066442017. View Article : Google Scholar : PubMed/NCBI
|
18
|
Klionsky DJ, Cuervo AM and Seglen PO:
Methods for monitoring autophagy from yeast to human. Autophagy.
3:181–206. 2007. View Article : Google Scholar : PubMed/NCBI
|
19
|
Fan T, Chen L, Huang Z, Wang W, Zhang B,
Xu Y, Mao Z, Hu H and Geng Q: Autophagy activation by rapamycin
before hypoxia-reoxygenation reduces endoplasmic reticulum stress
in alveolar epithelial cells. Cell Physiol Biochem. 41:79–90. 2017.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Mizushima N: Methods for monitoring
autophagy. Int J Biochem Cell Biol. 36:2491–2502. 2004. View Article : Google Scholar : PubMed/NCBI
|
21
|
Clevers H: The cancer stem cell: Premises,
promises and challenges. Nat Med. 17:313–319. 2011. View Article : Google Scholar : PubMed/NCBI
|
22
|
Yang MC, Wang HC, Hou YC, Tung HL, Chiu TJ
and Shan YS: Blockade of autophagy reduces pancreatic cancer stem
cell activity and potentiates the tumoricidal effect of
gemcitabine. Mol Cancer. 14:1792015. View Article : Google Scholar : PubMed/NCBI
|
23
|
Mizrak D, Brittan M and Alison M: CD133:
Molecule of the moment. J Pathol. 214:3–9. 2008. View Article : Google Scholar : PubMed/NCBI
|
24
|
Chen H, Luo Z, Dong L, Tan Y, Yang J, Feng
G, Wu M, Li Z and Wang H: CD133/prominin-1-mediated autophagy and
glucose uptake beneficial for hepatoma cell survival. PLoS One.
8:e568782013. View Article : Google Scholar : PubMed/NCBI
|
25
|
Bruix J and Sherman M: American
Association for the Study of Liver Diseases: Management of
hepatocellular carcinoma: An update. Hepatology. 53:1020–1022.
2011. View Article : Google Scholar : PubMed/NCBI
|
26
|
Van den Broeck A, Gremeaux L, Topal B and
Vankelecom H: Human pancreatic adenocarcinoma contains a side
population resistant to gemcitabine. BMC Cancer. 12:3542012.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Liu L, Liao JZ, He XX and Li PY: The role
of autophagy in hepatocellular carcinoma: Friend or foe.
Oncotarget. 8:57707–57722. 2017.PubMed/NCBI
|
28
|
Li P, Du Q, Cao Z, Guo Z, Evankovich J,
Yan W, Chang Y, Shao L, Stolz DB, Tsung A, et al: Interferon-γ
induces autophagy with growth inhibition and cell death in human
hepatocellular carcinoma (HCC) cells through interferon-regulatory
factor-1 (IRF-1). Cancer Lett. 314:213–222. 2012. View Article : Google Scholar : PubMed/NCBI
|
29
|
Tay Y, Kats L, Salmena L, Weiss D, Tan SM,
Ala U, Karreth F, Poliseno L, Provero P, Di Cunto F, et al:
Coding-independent regulation of the tumor suppressor PTEN by
competing endogenous mRNAs. Cell. 147:344–357. 2011. View Article : Google Scholar : PubMed/NCBI
|
30
|
Kohga K, Tatsumi T, Takehara T, Tsunematsu
H, Shimizu S, Yamamoto M, Sasakawa A, Miyagi T and Hayashi N:
Expression of CD133 confers malignant potential by regulating
metalloproteinases in human hepatocellular carcinoma. J Hepatol.
52:872–879. 2010. View Article : Google Scholar : PubMed/NCBI
|
31
|
Yang XR, Xu Y, Yu B, Zhou J, Qiu SJ, Shi
GM, Zhang BH, Wu WZ, Shi YH, Wu B, et al: High expression levels of
putative hepatic stem/progenitor cell biomarkers related to tumour
angiogenesis and poor prognosis of hepatocellular carcinoma. Gut.
59:953–962. 2010. View Article : Google Scholar : PubMed/NCBI
|
32
|
Song YJ, Zhang SS, Guo XL, Sun K, Han ZP,
Li R, Zhao QD, Deng WJ, Xie XQ, Zhang JW, et al: Autophagy
contributes to the survival of CD133+ liver cancer stem
cells in the hypoxic and nutrient-deprived tumor microenvironment.
Cancer Lett. 339:70–81. 2013. View Article : Google Scholar : PubMed/NCBI
|
33
|
Sun H, Zhang M, Cheng K, Li P, Han S, Li
R, Su M, Zeng W, Liu J, Guo J, et al: Resistance of glioma cells to
nutrient-deprived microenvironment can be enhanced by
CD133-mediated autophagy. Oncotarget. 7:76238–76249. 2016.
View Article : Google Scholar : PubMed/NCBI
|